Di Yi Cai Jing·2025-08-15 07:13Group 1 - Eli Lilly announced a $1.3 billion deal with AI pharmaceutical company Superluminal to accelerate AI drug development, particularly for small molecule drugs targeting obesity and other cardiometabolic diseases [1] - Superluminal's AI-driven drug discovery platform will be utilized by Eli Lilly to develop drugs targeting G protein-coupled receptors (GPCRs), which play a significant role in various physiological processes [1] - The obesity treatment market, where Eli Lilly currently holds a dominant position, is projected to reach a value of $150 billion over the next decade [1] Group 2 - Novo Nordisk is also focusing on GPCR small molecule drug development, having signed a deal worth up to $2.2 billion with Septerna to develop oral small molecule therapies targeting specific GPCRs for obesity and other cardiometabolic diseases [2] - In June, Novo Nordisk entered into a collaboration valued at over $800 million with Deep Apple to jointly develop and commercialize GPCR small molecule drugs [2] - GPCRs represent the largest and most diverse family of cell membrane receptors, with hundreds of different GPCRs regulating physiological mechanisms across nearly all organ systems in the human body [2]